Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00759759 · ClinicalTrials.gov registry record · Phase 1

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions

A Phase 1 study of Healthy, sponsored by Actavis.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT00759759: Completed Phase 1 study of Healthy, sponsored by Actavis.

NCT00759759 is a Phase 1 study of Healthy that has completed, run by Actavis. The registered enrollment target is 36 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00759759, a Phase 1 study of Healthy, has completed, sponsored by Actavis.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent oral dose of the commercially available reference product, KADIAN 2 x 100 mg capsules manufactured by Alpharma Branded Products Division Inc. when administered after a 10-hour overnight fast.

Conditions Studied

Interventions

  • DRUG morphine sulfate sustained-release capsules
  • DRUG KADIAN (morphine sulfate sustained-release) capsules

Study Locations (1)

Texas

  • CEDRA Clinical Research, LLC - Austin

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2004-09
Est. Completion 2004-10
Phase Phase 1
Actavis

79 total trials

What the finished NCT00759759 record still lists

NCT00759759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which morphine sulfate sustained-release capsules is the first listed.

NCT00759759 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00759759 about?

NCT00759759 is a clinical study titled "Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions". The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of morphine sulfate 200 mg sustained-release capsules manufactured by Alpharma Branded Products Division Inc. to an equivalent or...

What is the current status of trial NCT00759759?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-09. Estimated completion is 2004-10.

What conditions does trial NCT00759759 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00759759?

The interventions under investigation include: morphine sulfate sustained-release capsules (DRUG), KADIAN (morphine sulfate sustained-release) capsules (DRUG).

Who is sponsoring clinical trial NCT00759759?

This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00759759 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00759759's enrollment target sits among peer trials

36 595th of 1090 higher than 469 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00759759, the US trial registry maintained by the National Library of Medicine. NCT00759759 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.